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Gastric cancer is characterised by nonspecific symptoms and thus
patients often present at an advanced stage. Patients may present
with weight loss, anorexia, epigastric discomfort, and more
infrequently, early satiety or vomiting of blood. Diagnosis is by
endoscopy and biopsy and CT scans of the chest, abdomen and
pelvis are required to stage the disease. Endoscopic ultrasound
(EUS) allows direct visualisation of the gastric mucosa and has an
accuracy of up to 90% for T staging and 75% for N staging, which
is superior to CT scan and was widely implemented towards the
late 1990s (Dittler and Siewert, 1993; Matsumoto et al, 2000).
Staging laparoscopy has become an accepted pretreatment
evaluation for patients with localised disease for detecting occult
metastatic disease not visible on CT scan. This probably had the
greatest impact on staging in the 1990s when helical CT scans were
not routinely employed and detection rates of occult metastases
were up to 37% in some studies (Lowy et al, 1996; Asencio et al,
1997; Burke et al, 1997).
Surgical resection was the cornerstone of treatment for patients
with localised gastric cancer during this period and many studies
evaluating surgical techniques were conducted. Several studies
demonstrated that perioperative mortality for gastrectomy was
inversely related to the institutional gastrectomy volume (Birk-
meyer et al, 2002; Hannan et al, 2002). This has led to the
centralisation of care for gastric cancer with surgery generally
performed at larger centres by specialist surgeons.
Adjuvant therapy was not routine practice at this time, as the
supporting evidence was from relatively small studies. However,
a large randomised prospective study of 503 patients by the
Medical Research Council reported an improved progression-free
survival for perioperative chemotherapy with epirubicin,
cisplatin and 5FU (ECF) plus surgery vs surgery alone (HR 0.70
(95% CI: 0.56–0.88), P¼0.002) (Allum et al, 2005). The long-term
follow-up for this trial was reported and this has now translated
into an overall survival (OS) benefit for the perioperative
chemotherapy arm (HR 0.75 (95% CI: 0.60–0.93), P¼0.009)
(Cunningham et al, 2006). These results confirm the benefit of
perioperative chemotherapy and demonstrated an acceptable
postoperative mortality rate of 6%. Thus, perioperative che-
motherapy plus surgery has been adopted as standard practice in
the United Kingdom.
The management of advanced disease has developed signifi-
cantly during the 1990s with a change in clinical practice. Several
randomised studies demonstrated superior OS for chemotherapy
compared with best supportive care (Murad et al, 1993; Glimelius
et al, 1994). Trials were then conducted to evaluate combination
chemotherapy and ECF showed superior efficacy and quality of life
in two large randomised studies (Waters et al, 1999; Ross et al,
2002). Hence, ECF became the reference regimen for advanced
gastric cancer in the latter part of the 1990s. The Cochrane Review
of chemotherapy for advanced gastric cancer has recently concluded
that among the current chemotherapy combinations, ECF demon-
strated the best efficacy and tolerance (Wagner et al,2 0 0 5 ) .
A national study of 1002 patients evaluated the substitution
of capecitabine for infused-5FU and oxaliplatin for cisplatin
in the original ECF regimen in patients with previously
untreated advanced oesophago-gastric cancer. It reported that
capecitabine and oxaliplatin were as effective as 5FU and cisplatin.
Furthermore, OS was longer with epirubicin, oxaliplatin and
capecitabine (EOX) than ECF (median OS of 11.4 months) with a
hazard ratio for death for EOX of 0.80, 95% CI: 0.66–0.97;
(P¼0.02) (Cunningham et al, 2008).
There has been a consistent rise in 1-year survival of gastric
cancer between 1986 and 1999, and this reflects decreased
postoperative mortality and the use of chemotherapy for advanced
disease. There was a small improvement in 5-year survival, which
may be because of improved staging, patient selection for curative
resection and decreased postoperative mortality.
The deprivation gap is most marked in men for short-
term survival and has widened over time. One possible explanation
is that the patients from the more deprived group were less
likely to be referred to specialist centres for surgery until the late
1990s.
Predicted survival from period analysis suggests a continuing
increase in short- and long-term survival. There has been
considerable progress in the treatment of gastric cancer over the
last 10 years. Staging of localised disease has improved with the use
of EUS and laparoscopy, and more recently FDG PET has been
employed to help identify metastatic deposits. Perioperative
chemotherapy has now demonstrated a clear survival benefit for
localised disease and this combined with the use of specialist
surgical centres is likely to improve the outcome for these patients.
Chemotherapy for advanced gastric cancer has produced a modest
survival advantage and new chemotherapy combinations and
targeted therapy may increase this further.
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to ensure the optimal staging, diagnosis and management of gastric
cancer. Cancers of the body and antrum of the stomach are
associated with Helicobacter pylori infection and research is under-
way to evaluate the relationship of this infection with other possible
aetiogical factors, such as tobacco and diet. Gene expression profiling
and molecular markers are being studied to identify potential
prognostic and predictive factors for gastric cancer.
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